Lioton (Heparin Sodium)

Heparin sodium binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa. This cascade interruption prevents the conversion of fibrinogen to fibrin, thereby reducing clot formation. When applied topically, the effect remains localized, offering antithrombotic protection without systemic anticoagulation in most cases.

The specific dose and frequency of Lioton are determined by the prescribing healthcare professional based on the indication, size of the treatment area, and patient factors. The product is applied as a thin layer to the affected skin, and the prescriber provides exact instructions for each case.

Safety of topical heparin products during pregnancy and lactation has not been fully established. Use should be limited to situations where the potential benefit outweighs any possible risk, and only under medical supervision. Pregnant or nursing patients should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Lioton product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with systemic anticoagulants such as oral warfarin or injectable low‑molecular‑weight heparin, Lioton provides a localized effect, minimizing systemic exposure and associated bleeding risk. It is generally preferred for superficial vascular conditions where systemic therapy is unnecessary, though efficacy may be lower for deep or extensive thrombosis.

Store Lioton at room temperature, preferably below 25 °C. Keep the container tightly closed, protect it from moisture, direct sunlight and extreme temperatures. Do not freeze the product. Ensure the packaging remains intact until the point of use.

Lioton is applied directly to the skin of the affected area. The prescriber instructs the patient to clean the site, apply a thin, even layer of the product, and allow it to dry. Frequency of application varies with the clinical situation and is defined by the treating clinician.

Although rare, serious adverse events can include systemic anticoagulation leading to unexpected bleeding, severe allergic reactions such as anaphylaxis, and heparin‑induced thrombocytopenia, a potentially life‑threatening drop in platelet count. Patients should be monitored for signs of excessive bleeding, skin reactions, or unexplained bruising.

Lioton should be avoided in individuals with known hypersensitivity to heparin or any excipients, those with active uncontrolled bleeding, and patients receiving concurrent systemic anticoagulant therapy unless specifically directed by a physician. Caution is also advised for patients with a history of heparin‑induced thrombocytopenia.